Medicare Coverage Policy For COVID Drugs Underscores Importance Of Add-On Payments

Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.

hand with healthcare blocks (source: shutterstock)
Rule Clears Reimbursement Hurdles To Broad Access

The Center for Medicare and Medicaid Service’s decision to automatically provide Medicare add-on payments for existing and future hospital drugs to treat COVID-19 demonstrates the agency’s recognition that supplemental reimbursement is crucial for ensuring access to new treatments.

The policy is announced in an interim final rule released on 28 October that also addresses Medicare reimbursement for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet